The 2026 DEA Action on 7-OH: What Was Scheduled, and What Was Not

On July 6, 2026, the U.S. Drug Enforcement Administration published two notices of intent in the Federal Register to temporarily place several 7-hydroxymitragynine (7-OH) related substances into Schedule I of the Controlled Substances Act. Because this is a fast-moving area with real consequences for manufacturers and brands, here is a plain, sourced summary of what the action covers and what it does not.

This is general information, not legal advice. Confirm how any rule applies to a specific product with your own counsel.

What the notices cover

The first notice states the intent to schedule material containing 7-OH above a specified threshold, including its isomers, esters, ethers, and salts. The threshold is set at 0.05% 7-OH for the kratom plant. For material produced synthetically or derived from the plant and further processed into finished forms such as extracts, concentrates, edibles, or pressed pills, the threshold is 0.05% 7-OH or 1 milligram of 7-OH per article.

A second notice names three specific 7-OH-related synthetics: mitragynine pseudoindoxyl (MP), dihydro-7-hydroxymitragynine (MGM-15), and 9-fluoro-dihydro-7-hydroxymitragynine (MGM-16).

Per the notices, the temporary scheduling order was to be published on or after August 5, 2026, be in force on the date of publication, and remain in place for two years, with a possible one-year extension.

What the action does not target

According to the Congressional Research Service summary of the action, traditional botanical kratom leaf containing naturally occurring trace levels of 7-OH is not the target of the scheduling. The action is aimed at concentrated 7-OH above the threshold and the named semi-synthetic substances.

Where our products stand

We supply standardized single alkaloids, speciociliatine and mitragynine, in bulk. They are extracted solvent-free and DCM-free from the naturally occurring alkaloids in the leaf, not produced by semi-synthetic conversion, and contain none of the synthetics named in the action (mitragynine pseudoindoxyl, MGM-15, MGM-16).

If you are a brand reassessing your line, we co-pack and private-label these standardized, lot-tested tablets under your own brand. The chemistry behind speciociliatine and mitragynine is covered on our science hub.